Physician profile
Robert O Holmes
NPI 1053496349
$214,821.54
in general payments reported to CMS, 2019-2025
32 companies · $27K in 2025
The $27K reported for 2025 was more than what 94% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $11K · 2021: $24K · 2022: $18K · 2023: $31K · 2024: $42K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $79K · Food and Beverage: $11K · Travel and Lodging: $9,773 · Education: $32.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,632.50 |
| Food and Beverage | $10,767.93 |
| Travel and Lodging | $9,773.28 |
| Education | $32.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $76,010.71 | 2019-2025 | |
| Amgen INC. | $37,654.62 | 2019-2025 | Otezla, Enbrel, Krystexxa |
| Regeneron Healthcare Solutions, INC. | $32,142.58 | 2019 | |
| Mallinckrodt Hospital Products INC. | $32,124.86 | 2020-2025 | Acthar |
| Celgene Corporation | $22,498.32 | 2019-2024 | Zeposia |
| Genzyme Corporation | $2,943.17 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $1,678.40 | 2019-2025 | |
| Pfizer INC. | $1,536.38 | 2019-2025 | |
| Lilly USA, LLC | $1,446.51 | 2019-2025 | Taltz, Zepbound, Olumiant |
| Ucb, INC. | $1,111.50 | 2021-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $908.11 | 2019-2025 | Benlysta, Shingrix |
| Janssen Biotech, INC. | $755.68 | 2019-2023 | Tremfya, Simponi, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $744.94 | 2021-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $702.39 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $647.96 | 2019-2023 | Krystexxa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $450.52 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.30 | 2019-2024 | Ofev |
| E.R. Squibb & Sons, L.L.C. | $299.27 | 2019-2023 | Orencia |
| Genentech USA, INC. | $163.73 | 2019-2025 | Actemra |
| Bayer Healthcare Pharmaceuticals INC. | $149.95 | 2025 | |
| Ani Pharmaceuticals, INC. | $140.07 | 2024-2025 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $121.72 | 2025 | |
| Octapharma USA, INC. | $41.73 | 2022 | |
| Abbott Laboratories | $28.66 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $22.72 | 2024 | Gvoke Hypopen |
| Mallinckrodt Enterprises LLC | $22.27 | 2019 | |
| Sequel Med Tech, LLC | $21.37 | 2025 | Twiist |
| Edwards Lifesciences Corporation | $20.29 | 2024 | Sapien 3 Ultra Resilia |
| Pharming Healthcare, INC. | $19.01 | 2024 | Ruconest |
| Medtronic, INC. | $18.02 | 2023 | Intellis Adaptivestim |
| Sanofi-Aventis U.S. LLC | $17.86 | 2020 | |
| Daiichi Sankyo INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.